Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of generic linagliptin 5 mg vs originator TRAJENTA in healthy Thai volunteers under fasting conditions
TCTR20221116003Phase 1Unknown
- Sponsor
- Bio-innova
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Status: unknown.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20221116003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221116003.